Hepatitis D Virus: A Call to Screening
- PMID: 27540336
- PMCID: PMC4988222
Hepatitis D Virus: A Call to Screening
Abstract
Hepatitis D virus causes an aggressive viral hepatitis with a virulent course of progression to cirrhosis and hepatic decompensation. It relies on hepatitis B coinfection for its pathogenesis and propagation. Hepatitis D virus had become the forgotten virus, with reduced public awareness, medical interest, and research support. Recently, there has been a resurgence of awareness and interest in hepatitis D, with improvements in diagnostic testing and establishment of international collaborative efforts to improve therapy. This article provides a framework to understand the impetus for increased screening as well as to identify key issues toward which collaborative efforts can be directed.
Keywords: Hepatitis delta; cirrhosis; interferon; pegylated interferon; prenylation inhibitors.
References
-
- Rizzetto M. The delta agent. Hepatology. 1983;3(5):729–737. - PubMed
-
- Rizzetto M. Hepatitis D: thirty years after. J Hepatol. 2009;50(5):1043–1050. - PubMed
-
- Wedemeyer H, Yurdaydin C, Ernst S, et al. HIDIT-2 Study Group. Prolonged therapy of hepatitis delta for 96 weeks with pegylated-interferon-α-2a plus tenofovir or placebo does not prevent HDV RNA relapse after treatment: the HIDIT-2 study. J Hepatol. 2014;60(1):S2–S3.
-
- Rizzetto M, Ponzetto A, Forzani I. Hepatitis delta virus as a global health problem. Vaccine. 1990;8(suppl):S10–S14. discussion S21-S23. - PubMed
-
- Rizzetto M, Alavian SM. Hepatitis delta: the rediscovery. Clin Liver Dis. 2013;17(3):475–487. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous